Sprycel (dasatinib) — United Healthcare

Initial criteria

• Diagnosis of cutaneous melanoma
• AND Tumors are metastatic or unresectable
• AND Contains activating mutations of KIT
• AND Used as second-line or subsequent therapy for disease progression, intolerance, and/or projected risk of progression with BRAF-targeted therapy

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Sprycel therapy

Approval duration

12 months